Due to its Open Access nature, the impact of the SGC’s outputs is reaching beyond the traditional circles involved in drug discovery.

It opens several stages of the drug discovery to participation by different sectors of society, including patient groups, governments, national health systems, charities, entrepreneurs and investors – direct stakeholders that are normally consumers rather than actors in the process.

We are always welcoming other sectors to engage in further discussion with us about the best way of taking this model further forward, to the benefit of all the patients – present and future ones.

glqxz9283 sfy39587stf02 mnesdcuix8